Clinical trials: MTOR
Post-hemorrhagic Hydrocephalus (PHH)
Ventricular mTOR Inhibition to Prevent Hydrocephalus After Brain Hemorrhage
Hydrocephalus is a serious condition in which fluid builds up inside the brain, often requiring lifelong surgical placement of a shunt to drain excess cerebrospinal fluid (CSF).
- Trial name
- VENTURE-PHH (NCT07662174)
- Testing
- Sirolimus (Rapamune®)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Massachusetts General Hospital
Breast Cancer
Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
There are no treatments specifically approved after recurrence or progression on a non steroidal aromatase inhibitors (NSAI). In light of the need for new treatment options for postmenopausal women after failure of prior NSAI…
- Trial name
- BOLERO-2 (NCT00863655)
- Testing
- Everolimus, Exemestane
- Where
- 200 sites in United States, Australia and 22 more
- Volunteers
- 724 people
- Sponsor
- Novartis Pharmaceuticals
Leiomyosarcoma, Liposarcoma
Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED)
The purpose of this study is to assess the efficacy of ridaforolimus when administered once daily for 5 consecutive days (QDx5) every two weeks in participants with advanced sarcoma.
- Conditions
- Leiomyosarcoma, Liposarcoma, Osteosarcoma, Sarcoma, Soft Tissue
- Trial name
- NCT00093080
- Testing
- ridaforolimus
- Volunteers
- 216 people
- Sponsor
- Merck Sharp & Dohme LLC
Tuberous Sclerosis Complex
Clinical Study of NPC-12Y Gel in Patients With Skin Lesions Associated With TSC
The purpose of this study is to investigate the efficacy and safety of NPC-12Y gel compared with placebo for skin lesions associated with tuberous sclerosis.
- Trial name
- NCT05495425
- Testing
- NPC-12Y gel
- Where
- 5 sites in Japan
- Volunteers
- 43 people
- Sponsor
- Nobelpharma
Advanced Solid Tumors
A Study of Temsirolimus Plus Capecitabine in Patients With Advanced Cancer
This study is for people with advanced cancer for which no curative treatment exists. The purpose of this study is to test the safety and effectiveness of the combination of the drugs Temsirolimus and Capecitabine and see what…
- Trial name
- NCT01050985
- Testing
- Temsirolimus and capecitabine
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Georgetown University
Lung Cancer
Itraconazole in Non Small Cell Lung Cancer
Circulating levels of angiogenic factors have been correlated with aggressive tumor growth, prediction of metastasis and prognosis in a wide range of solid tumors, including non-small cell lung cancer.
- Trial name
- NCT03664115
- Testing
- Itraconazole 200 mg, Chemotherapy
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Ain Shams University
Carcinoma, Renal Cell
Exploratory Study Evaluating Fluorodeoxyglucose - Position Emission Tomography as a Predictive Marker for Therapy With RAD001 in Metastatic Renal Cell Cancer
The purpose of this study is to learn if PET scanning can predict the degree of tumor shrinkage with the study drug RAD001 in subjects who have advanced renal cancer.
- Trial name
- NCT00529802
- Testing
- RAD001
- Where
- 5 sites in United States
- Volunteers
- 60 people
- Sponsor
- University of Chicago
PI3K Gene Mutation, AKT Gene Mutation
Bile Acids in Acute Insulin Resistance
This is a prospective observational study with a primary goal of monitoring changes in circulating bile acid profiles and parameters of glucose and lipid metabolism prior, during, and after cancer treatment with agents that…
- Conditions
- PI3K Gene Mutation, AKT Gene Mutation, MTOR Gene Mutation, Cancer
- Trial name
- NCT05571670
- Testing
- Drug-induced acute insulin resistance due to PI3K inhibitor, AKT inhibitor, or mTOR inhibitor
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Columbia University
Colorectal Cancer (CRC), Specimens Are to be Collected From Subjects Who Are Having or Have Had a Fluid or Tissue Removed, a Biopsy or a Blood or Bone Marrow Draw
CYFIP1 and PKM2 Synergistically Regulate ROS and Glycolysis in Colorectal Cancer Through the AKT/mTOR/HIF-1α Cascad
Collect some tumor tissue specimens from patients who have undergone colorectal cancer surgery and conduct experiments such as immunohistochemistry to observe the expression of related genes in colorectal cancer.
- Trial name
- NCT07197151
- Testing
- Perform surgery on patients with colorectal cancer and collect cancer and adjacent tissue specimens
- Where
- China
- Volunteers
- 32 people
- Sponsor
- hui hou
SOLID TUMOR
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus
Preclinical studies and clinical observations have shown the Phosphoinositide 3-kinase (PI3K) /Protein kinase B (AKT) /mammalian (mechanistic) target of Rapamycin (known as the 'mTOR-pathway') signaling to be deregulated in…
- Trial name
- NCT02441543
- Where
- Italy
- Volunteers
- 45 people
- Sponsor
- Istituto Clinico Humanitas
Mucosal Melanoma, Recurrent Melanoma
Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV
The purpose of this study is to find out how often two investigational drugs that are given together will shrink the patient's tumor and how well they will prolong the time it takes their tumor to grow.
- Conditions
- Mucosal Melanoma, Recurrent Melanoma, Stage IV Melanoma
- Trial name
- NCT01166126
- Testing
- temsirolimus, selumetinib, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- National Cancer Institute (NCI)
BK Viremia, BK Nephropathy
Using mTOR Inhibitors in the Prevention of BK Nephropathy
BK virus infections after kidney transplant are increasing and can result in damage to the transplanted kidney. Currently, the universally accepted treatment is to decrease the strength of the antirejection medications but it is…
- Trial name
- NCT01649609
- Testing
- Tacrolimus, Mycophenolate acid, Sirolimus
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Columbia University
Breast Neoplasms, mTor Protein
Tamoxifen-RAD001 Versus Tamoxifen Alone in Patients With Anti-aromatase Resistant Breast Metastatic Cancer
Tamoxifen is a classical treatment for breast metastatic cancer after 3rd generation anti-aromatase hormonotherapy in adjuvant or in metastatic line.
- Trial name
- NCT01298713
- Testing
- Tamoxifen, Everolimus
- Where
- France
- Volunteers
- 111 people
- Sponsor
- ARCAGY/ GINECO GROUP
Her2-negative Metastatic Breast Cancer, Her2-negative Locally Advanced Breast Cancer
Study to Compare Vinorelbine In Combination With the mTOR Inhibitor Everolimus vs. Vinorelbin Monotherapy for Second-line Treatment in Advanced Breast Cancer
The purpose of this study is Examination of the superiority of a combination of vinorelbine with the mTOR Inhibitor Everolimus vs. vinorelbine monotherapy for second-line treatment in advanced breast cancer.
- Trial name
- VicTORia (NCT01520103)
- Testing
- Vinorebine, Everolimus, Vinorelbine
- Where
- Germany
- Volunteers
- 139 people
- Sponsor
- AIO-Studien-gGmbH
Metastatic Pancreatic Cancer
Everolimus, Cetuximab and Capecitabine in Patients With Metastatic Pancreatic Cancer
In this study the investigators want to determine the activity and safety of concurrent interruption of the MAPK and PI3K pathways by EGFR and mTOR inhibition in patients with metastatic pancreatic cancer.
- Trial name
- NCT01077986
- Testing
- Capecitabine, Cetuximab, Everolimus
- Where
- Netherlands
- Volunteers
- 35 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Renal Cell Cancer, Cancer
Study of Nelfinavir and Temsirolimus in Patients With Advanced Cancers
In the present study the investigators want to explore the safety, pharmacokinetics, and activity of the combination of temsirolimus and nelfinavir, both agents with PI3K /Akt/mTOR inhibiting activity, in patients with advanced…
- Trial name
- I-NET (NCT01079286)
- Testing
- Nelfinavir and temsirolimus
- Where
- Netherlands
- Volunteers
- 18 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Malignant Peripheral Nerve Sheath Tumors, MPNST
SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors
To determine the clinical response rate of everolimus in combination with bevacizumab for patients with chemotherapy refractory sporadic or neurofibromatosis type 1 (NF1) associated malignant peripheral nerve sheath tumor…
- Conditions
- Malignant Peripheral Nerve Sheath Tumors, MPNST, Sarcoma
- Trial name
- NCT01661283
- Testing
- everolimus, bevacizumab
- Where
- 12 sites in United States
- Volunteers
- 25 people
- Sponsor
- Sarcoma Alliance for Research through Collaboration
Disorder Related to Renal Transplantation
Efficacy of a Quadruple Immunosuppressor Regimen With mTOR Inhibitors in Sensitized Kidney Transplant Patients
In this study, sensitized renal transplant recipients, who present an increased risk of acute rejection, will be evaluated for the benefit of quadruple immunosuppression, adding sirolimus to the traditional scheme with…
- Trial name
- QIS (NCT06584773)
- Testing
- Everolimus, standard maintenance immunosuppression
- Where
- Brazil
- Volunteers
- 80 people
- Sponsor
- University of Sao Paulo General Hospital
Tuberous Sclerosis Complex, Epilepsy
Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study
This trial is a Phase II randomized, double-blind, placebo controlled multi-site study to evaluate the safety and efficacy of early sirolimus to prevent or delay seizure onset in TSC infants.
- Trial name
- TSC-STEPS (NCT05104983)
- Testing
- Sirolimus
- Where
- 8 sites in United States
- Volunteers
- 64 people
- Sponsor
- Darcy Krueger
Chronic Myeloid Leukemia
RAD001 in Patients With Chronic Phase Chronic Myeloid Leukemia w/ Molecular Disease.
Patients participating in this study will have a diagnosis of Chronic Myeloid Leukemia. This study will evaluate whether the addition of an investigational drug called RAD001 given together with Imatinib will better target…
- Trial name
- NCT01188889
- Testing
- RAD001, Imatinib
- Where
- United States
- Sponsor
- University of Michigan Rogel Cancer Center